Weekly Paclitaxel and Cyclophosphamide in Metronomic Administration : Dose Escalation Study of Weekly Paclitaxel

Inclusion Criteria:

* Patient with cancer histologically proved
* No other therapeutic proposal after discussion in multidisciplinary consultation
* Radiological evidence of the evolving nature of the disease
* Measurable disease with at least one measurable lesion according to the criteria RECIST 1.1
* At least 28 days since prior treatment(systemic treatment or major surgery)
* Patient who have recovered from any previous toxicity
* Man or woman de ≥ 18 years and ≤ 65 years
* Performance Status (ECOG) ≤ 2 within 7 days before inclusion
* Polynuclear neutrophils ≥ 1500/mm3, platelets ≥ 100 000/mm3, Hemoglobin ≥ 9 g/dl
* Serum Albumin ≥ 36 g/l and lymphocytes ≥ 700/mm3
* Total bilirubin and SGPT/ALT and SGOT/AST ≤ 3 ULN(≤ 5 ULN if liver metastases)
* Creatinine in normal ranges and Creatinine clearance \> 60 ml/min (Cockcroft formulae)
* Central venous access
* Negative pregnancy test for women who may be pregnant within 7 days before inclusion
* Effective contraceptive during the treatment period and up to 6 months after the end of treatment (for patients of both sexes during their reproductive and child-bearing age and their partners)
* Patient covered by government health insurance
* Informed consent signed by the patient before any specific study procedure

Exclusion Criteria:

* Prior treatment by Paclitaxel
* Oral treatment impossible
* Known dysphagia, malabsorption or maldigestion
* Pre-existing neuropathy clinically symptomatic
* Known leptomeningeal brain metastases
* Known allergy to Cremophor, to Paclitaxel or one of its excipients (especially polyoxyethylene castor oil), to Cyclophosphamide or one of its excipients (lactose, sucrose)
* Active and uncontrolled infection
* Acute urinary tract infection, pre-existing hemorrhagic cystitis
* Diabetes insipidus
* History or progressive psychiatric illness
* Persons under guardianship or detainees
* Unable for medical follow-up (geographic, social or mental reasons)
* Pregnant, or likely to be or breastfeeding women
* Absence of effective contraception for the duration of treatment and 6 months after completion of therapy (for patients of both sexes in childbearing or reproductive age and their partners)